Technical Analysis for VIRX - Viracta Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 0.99 | -0.60% | -0.01 |
VIRX closed down 0.6 percent on Monday, March 18, 2024, on 87 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
200 DMA Support | Bullish | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Gapped Down | Weakness | 0.00% | |
200 DMA Support | Bullish | -0.60% | |
Wide Bands | Range Expansion | -0.60% | |
Crossed Above 200 DMA | Bullish | 2.06% | |
180 Bullish Setup | Bullish Swing Setup | 2.06% |
Alert | Time |
---|---|
Possible Inside Day | about 7 hours ago |
Gap Down Closed | about 8 hours ago |
60 Minute Opening Range Breakout | about 8 hours ago |
200 DMA Support | about 9 hours ago |
Gap Down Partially Closed | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/11/2024
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.38 |
52 Week Low | 0.43 |
Average Volume | 95,816 |
200-Day Moving Average | 0.96 |
50-Day Moving Average | 0.69 |
20-Day Moving Average | 0.86 |
10-Day Moving Average | 0.93 |
Average True Range | 0.09 |
RSI (14) | 66.56 |
ADX | 33.01 |
+DI | 24.56 |
-DI | 9.90 |
Chandelier Exit (Long, 3 ATRs) | 0.78 |
Chandelier Exit (Short, 3 ATRs) | 0.89 |
Upper Bollinger Bands | 1.07 |
Lower Bollinger Band | 0.64 |
Percent B (%b) | 0.81 |
BandWidth | 50.04 |
MACD Line | 0.09 |
MACD Signal Line | 0.08 |
MACD Histogram | 0.0061 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 1.08 | ||||
Resistance 3 (R3) | 1.08 | 1.04 | 1.07 | ||
Resistance 2 (R2) | 1.04 | 1.02 | 1.05 | 1.06 | |
Resistance 1 (R1) | 1.02 | 1.01 | 1.03 | 1.02 | 1.05 |
Pivot Point | 0.98 | 0.98 | 0.99 | 0.99 | 0.98 |
Support 1 (S1) | 0.96 | 0.96 | 0.97 | 0.96 | 0.93 |
Support 2 (S2) | 0.92 | 0.95 | 0.93 | 0.92 | |
Support 3 (S3) | 0.90 | 0.92 | 0.92 | ||
Support 4 (S4) | 0.90 |